TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...

Eisai and Biogen's Alzheimer's drug Leqembi continues to show promise in slowing disease progression, with no new safety issues observed over four years. The injectable form of Leqembi is under U.S.

Eisai expects that Leqembi, which is for Alzheimer's, is going to be a trillion dollar product. Lenvima is working on a major foray in combination with Merck's Keytruda into lung cancer.

Eisai: Looking To Upside Targets Following Leqembi Full Approval Jul. 09, 2023 10:00 AM ET Eisai Co., Ltd. (ESAIY) Stock, ESALF Stock BIIB, ESAIY, ESALF 5 Comments ...

Eisai now expects Leqembi sales to total JPY 42.5 billion for the period, down from JPY 56.5 billion announced in May. Leqembi sales for the first half of Eisai's FY2024 amounted to JPY 16.3 ...